Tag Archive for: Switzerland

Source: Swiss Biotech Report 2026
Report

Switzerland’s biotech sector defies tough markets with record revenue

If one follows the figures in the Swiss Biotech Report 2026, the green lights are more prominent than the red warning signals. The Swiss biotech industry continued its growth momentum in 2025 and even reached new record highs. According to the industry report presented in early May at Swiss Biotech Day in Basel, total revenue among companies classified as biotech — which in this case explicitly does not include Roche and Novartis, for example — rose to CHF 7.5 billion, up from CHF 7.2 billion the previous year. The drivers were a growing number of market-ready products and persistently strong demand for specialized CDMO services.

Read more
immo-wegmann-DgRNOR1z0s4-unsplashPic by Immo Wegmann via Unsplash
Funding

Jeito Capital raises record US$1.2bn to bankroll European biopharma’s next generation

Jeito Capital has closed its second dedicated biopharma fund, Jeito II, on a record US$1.2 billion (€1 billion), making it the largest fund ever raised by a fully independent European biopharma-focused private equity firm. The move firmly places Jeito among the leading global backers of clinical stage innovation.

Read more
Novatis.jpgNovartis Group
Switzerland

Something of a shopping spree: Novartis to acquire US-based Excellergy for up to $2bn

Novartis is back on the acquisition trail, agreeing to buy California-based Excellergy for up to $2bn. The antibody Exl-111 is intended to strengthen its allergy pipeline and go beyond the current standard of care. The deal is part of a broader string of acquisitions aimed at systematically expanding the group’s innovation base.

Read more
Novartis HQ in Basel, Switzerlandadobe stock photos - Michael Derrer Fuchs
Switzerland

Novartis strikes another billion-dollar oncology deal with acquisition of an early PI3Kalpha oral therapy

Novartis is pressing ahead with its aggressive expansion strategy in oncology, striking again: the Basel-based group is acquiring a novel PI3Kalpha inhibitor from Synnovation Therapeutics for up to USD 3 billion.

Read more
Roche Headquarter BaselRoche
Breast Cancer

Roche breast cancer drug falls short of expectations (for now)

Setback after earlier optimism: the Roche drug giredestrant has delivered mixed clinical data. Several clinical trials had suggested the drug could play an important role in the treatment of hormone-dependent breast tumours and potentially become a blockbuster for the company. Now, however, a key Phase III study has failed to meet its primary endpoint, even as regulatory submissions are already under way.

Read more
Initial high blood pool was followed by specific uptake in primary (red arrow) & metastatic lesions (blue) after 116h in line with MP0712 MoAMolecular Partners AG & NuMeRI, presentation Feb. 2026
Radiopharmaceuticals

Radioligands give Molecular Partners new momentum in a market already at full speed

The Zurich-based developer is increasingly focusing its pipeline on radiopharmaceutical cancer therapies. A recent development agreement with isotope specialist Eckert & Ziegler marks another step in that direction. The collaboration aims to develop and manufacture so-called Radio-DARPin therapeutics, in which targeted protein molecules deliver radioactive isotopes directly to tumours. Early clinical data on the DARPin molecules in combination with radioisotopes suggest targeted tumour localisation. Proof of efficacy, however, is still pending.

Read more
araris technology adc webAraris Biotech AG
Antibody drug conjugates

Swiss-Japanese ADC player Araris expands Chugai pact with $780m licensing agreement

Zurich-based oncology biotech Araris Biotech AG has entered into a research collaboration with an option to license with Japan’s Chugai Pharmaceutical, a subsidiary of Roche. The aim of the partnership is to develop next-generation antibody–drug conjugates (ADCs). While Araris itself is now Japanese-owned – a wholly owned subsidiary of Taiho Pharmaceutical, part of the Otsuka Group – its research activities remain firmly rooted in Zurich. That presence was highlighted last year when the Strüngmann brothers, German billionaire twins, awarded a prize to the company’s founders.

Read more
Switzerland Map design with flag and light background vectorFreepik.com
Antibody

This Memo sticks: CSL bites in Switzerland for antibody collaboration

The Australian–Swiss plasma specialist CSL is relying on technology from Switzerland for recombinant polyclonal immunoglobulins (IgG). With Memo Therapeutics, the company has entered into a collaboration and option agreement with a total potential value of up to CHF 265 million. This is good news for Memo, while CSL, following substantial job cuts including in Marburg, could also use some different headlines for a change.

Read more
Lonza_Teaser_EBM.pngLonza Group
CDMO

CDMOs dominate the headlines – and Lonza delivers a clear message of strength

CDMOs are currently setting the agenda across the industry. Alongside peers such as Vetter, Lonza has now delivered a clear statement of intent: strong results, sharper focus and an even more determined commitment to its core business. But the stronger investment strategy internationally frightens Switzerland – at least some analysts.

Read more
Roche Headquarter BaselRoche
Roche

Roche: strong growth in all world regions and a full pipeline in late stage

Roche made a clear statement in 2025. The Basel-based group increased sales by 7% at constant exchange rates to CHF 61.5bn (€67bn) and lifted core operating profit by as much as 13%. For many observers, this represents far more than just a solid set of annual results.

Read more